Clinical Trial Update: Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating bevacizumab and erlotinib in recurrent or metastatic head and neck squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Squamous Cell Carcinoma of Hypopharynx
• Squamous Cell Carcinoma of Larynx
• Squamous Cell Carcinoma of Lip and Oral Cavity
• Squamous Cell Carcinoma of Nasopharynx
• Squamous Cell Carcinoma of Oropharynx
• Squamous Cell Carcinoma of Paranasal Sinus and Nasal Cavity

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx | Phase 1, Phase 2 | Status: COMPLETED